Nomura Holdings
APGE icon

Nomura Holdings’s Apogee Therapeutics APGE Stock Holding History

Nomura Holdings’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.24M Buy
+26,600
New +$1.93M 0.01% 894

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Nomura Holdings's APGE Position: Q1 2026 in Review

Nomura Holdings increased its Apogee Therapeutics (APGE) stake by 15% in Q1 2026, buying an estimated $847K and bringing the position to 88,561 shares worth $7.45M. The position accounts for 0.02% of the portfolio, ranked #515.

Nomura Holdings first reported a position in APGE in Q4 2025 and has held it in 2 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Nomura Holdings held 88,561 shares of Apogee Therapeutics worth $7.45M as of Q1 2026.
  • Nomura Holdings bought 11,663 Apogee Therapeutics shares in Q1 2026, an estimated $847K.
  • Apogee Therapeutics made up 0.02% of Nomura Holdings's portfolio in Q1 2026, its #515 holding.
  • Nomura Holdings first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.